Reduced production of IFN-γ and LT-α is associated with successful prednisone therapy in patients with acquired hemophilia A: A pilot study

Kruse‐Jarres, Rebecca; Fang, Jian; Leissinger, Cindy; Ganapamo, Frédéric

doi:10.1016/j.thromres.2011.06.032

Cited by 2 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among these potential corticosteroid efficacy biomarkers, some have been previously reported showing steroid-responsive decreases in animal model systems or other adult inflammatory disorders. MMP12 was reported to be decreased by dexamethasone in an asthmatic mouse model 28 , CCL22 by dexamethasone in patients with atopic dermatitis 22 , FCER2 by prednisone in patients with giant cell arteritis 29 , LTa1/b2 by prednisone in patients with acquired hemophilia 30 , and IGFBP2 by deflazacort after renal transplantation 31 . The corticosteroid-responsive decreases in serum concentrations of the remaining markers IL22RA2, LY9, ITGa1/b1, ANGPT2 and FGG by corticosteroids are novel to our report.…”

Section: Discussionmentioning

confidence: 99%

Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children

Hathout

Conklin

Seol

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Corticosteroids are extensively used in pediatrics, yet the burden of side effects is significant. Availability of a simple, fast, and reliable biochemical read out of steroidal drug pharmacodynamics could enable a rapid and objective assessment of safety and efficacy of corticosteroids and aid development of corticosteroid replacement drugs. To identify potential corticosteroid responsive biomarkers we performed proteome profiling of serum samples from DMD and IBD patients with and without corticosteroid treatment using SOMAscan aptamer panel testing 1,129 proteins in <0.1 cc of sera. Ten pro-inflammatory proteins were elevated in untreated patients and suppressed by corticosteroids (MMP12, IL22RA2, CCL22, IGFBP2, FCER2, LY9, ITGa1/b1, LTa1/b2, ANGPT2 and FGG). These are candidate biomarkers for anti-inflammatory efficacy of corticosteroids. Known safety concerns were validated, including elevated non-fasting insulin (insulin resistance), and elevated angiotensinogen (salt retention). These were extended by new candidates for metabolism disturbances (leptin, afamin), stunting of growth (growth hormone binding protein), and connective tissue remodeling (MMP3). Significant suppression of multiple adrenal steroid hormones was also seen in treated children (reductions of 17-hydroxyprogesterone, corticosterone, 11-deoxycortisol and testosterone). A panel of new pharmacodynamic biomarkers for corticosteroids in children was defined. Future studies will need to bridge specific biomarkers to mechanism of drug action, and specific clinical outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children

Hathout

Conklin

Seol

et al. 2016

Sci Rep

View full text Add to dashboard Cite

show abstract

“…In Dr. DiMichele's own words, "there is too much left to do." [43,44], acquired hemophilia A [45], and other coagulation disorders, such as von Willebrand disease. She has been an active investigator for numerous research studies and Principle Investigator for 2 investigator-initiated, multiinstitutional clinical trials of treatments for individuals with hemophilia A and factor VIII inhibitors: the Rituximab for Inhibitors in Congenital Hemophilia (RICH) study [46] and the ProFEIBA study of anti-inhibitor coagulant complex prophylaxis [44].…”

Section: Dr Hsieh's Perspectivementioning

confidence: 99%